Finding ways to overcome resistance to pancreatic cancer treatments
Project 1: Overcoming therapeutic resistance in pancreatic cancer through epigenetic reprogramming
This study is looking at how changes in the genes of pancreatic cancer can affect how well treatments work, and it's for people with pancreatic ductal adenocarcinoma who want to know if new approaches might help make their current treatments more effective.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Salk Institute for Biological Studies NIH-funded |
| Lab location | 1 site (La Jolla, UNITED STATES) |
| Project ID | NIH-10883559 on NIH RePORTER |
What this research studies
This research focuses on pancreatic ductal adenocarcinoma (PDA), a challenging cancer known for its resistance to standard treatments. The team is investigating how changes in the cancer's genetic and epigenetic makeup affect its response to therapies. They will use both drug treatments and genetic techniques to explore how inhibiting certain proteins can make the cancer more susceptible to existing treatments. By studying human organoid models, they aim to understand how different genetic mutations influence treatment responses.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma who have not responded well to conventional therapies.
Not a fit: Patients with early-stage pancreatic cancer or those who have not yet undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with pancreatic cancer.
How similar studies have performed: Previous research has shown promise in using epigenetic approaches to enhance cancer treatment effectiveness, suggesting potential for success in this area.
Where this research is happening
La Jolla, UNITED STATES
- Salk Institute for Biological Studies — La Jolla, United States (Active)
Researchers
- Principal investigator: Evans, Ronald M — Salk Institute for Biological Studies
- Study coordinator: Evans, Ronald M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.